

Supporting Scientific References

Organized by the categories measured in a comprehensive metabolic blood panel

Glucose Regulation

1. de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? *Br J Cancer*. 2014;110(9):2361-2368.
2. McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. *Ann Intern Med*. 2003;139(10):802-809.
3. Pan K, Nelson RA, Wactawski-Wende J, Lee DJ, Manson JE, Aragaki AK, et al. Insulin resistance and cancer-specific and all-cause mortality in postmenopausal women: the Women's Health Initiative. *J Natl Cancer Inst*. 2020;112(2):170-178.
4. Saboori S, Rad EY, Birjandi M, Mohiti S, Falahi E. Serum insulin level, HOMA-IR and prostate cancer risk: a systematic review and meta-analysis. *Diabetes Metab Syndr*. 2019;13(1):110-115.
5. Zhong GC, Ye MX, Cheng JH, Zhao Y, Gong JP. HbA1c and risks of all-cause and cause-specific death in subjects without known diabetes: a dose-response meta-analysis of prospective cohort studies. *Sci Rep*. 2016;6:24071.

Growth Signaling

1. Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. *Lancet Oncol*. 2010;11(6):530-542.
2. Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. *Trends Endocrinol Metab*. 2010;21(10):610-618.
3. Travis RC, Appleby PN, Martin RM, Holly JMP, Albanes D, Black A, et al. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. *Cancer Res*. 2016;76(8):2288-2300.

Inflammatory Markers

1. Aguilar-Cazares D, Chavez-Dominguez R, Marroquin-Muciño M, Perez-Medina M, Benito-Lopez JJ, Camarena A, Rumbo-Nava U, Lopez-Gonzalez JS. The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. *Front Endocrinol (Lausanne)*. 2022;13:929572.
2. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. *J Clin Oncol*. 2009;27(13):2217-2224.
3. Cui X, Jia Z, Chen D, Xu C, Yang P. The prognostic value of the C-reactive protein to albumin ratio in cancer: an updated meta-analysis. *Medicine (Baltimore)*. 2020;99(14):e19165.
4. Shiao SPK, Lie A, Yu CH. Meta-analysis of homocysteine-related factors on the risk of colorectal cancer. *Oncotarget*. 2018;9(39):25681-25697.

5. Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C. C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: a systematic review. *PLoS One*. 2015;10(12):e0143080.
6. Xu J, Zhao X, Sun S, Ni P, Li C, Ren A, Wang W, Zhu L. Homocysteine and digestive tract cancer risk: a dose-response meta-analysis. *J Oncol*. 2018;2018:3720684.

CBC & Immune Ratios

1. Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du P, Wang Q, Yang W. Prognostic role of pretreatment blood neutrophil-to-lymphocyte ratio in advanced cancer survivors: a systematic review and meta-analysis of 66 cohort studies. *Cancer Treat Rev*. 2017;58:1-13.
2. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocana A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Cancer Epidemiol Biomarkers Prev*. 2014;23(7):1204-1212.
3. Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2014;106(6):dju124.

Lipids

1. Baneu P, Văcărescu C, Drăgan SR, Cirin L, Lazăr-Höcher AI, Cozgarea A, et al. The triglyceride/HDL ratio as a surrogate biomarker for insulin resistance. *Biomedicines*. 2024;12(7):1493.
2. Borgquist S, Butt T, Almgren P, Shiffman D, Stocks T, Orho-Melander M, Manjer J, Melander O. Apolipoproteins, lipids and risk of cancer. *Int J Cancer*. 2016;138(11):2648-2656.
3. Katzke VA, Sookthai D, Johnson T, Kühn T, Kaaks R. Blood lipids and lipoproteins in relation to incidence and mortality risks for cancer and cardiovascular disease in the prospective EPIC-Heidelberg cohort. *BMC Med*. 2017;15(1):218.
4. Liu T, Zhou Q, Wang Y, Wang H, Liu C, Zhang H, et al. Association between the TyG index and TG/HDL-C ratio as insulin resistance markers and the risk of colorectal cancer. *BMC Cancer*. 2022;22(1):1007.
5. Suzuki K, Ito Y, Wakai K, Kawado M, Hashimoto S, Toyoshima H, et al. Serum oxidized low-density lipoprotein levels and risk of colorectal cancer: a case-control study nested in the Japan Collaborative Cohort Study. *Cancer Epidemiol Biomarkers Prev*. 2004;13(11 Pt 1):1781-1787.
6. Yang L, Sun J, Li M, Long Y, Zhang D, Guo H, et al. Oxidized low-density lipoprotein links hypercholesterolemia and bladder cancer aggressiveness by promoting cancer stemness. *Cancer Res*. 2021;81(22):5720-5732.

Minerals

1. Chaigne-Delalande B, Li FY, O'Connor GM, Lukacs MJ, Jiang P, Zheng L, Shatzer A, Biancalana M, Pittaluga S, Matthews HF, Jancel TJ, Bleesing JJ, Marsh RA, Kuijpers TW, Nichols KE, Lucas CL, Nagpal S, Mehmet H, Su HC, Cohen JI, Uzel G, Lenardo MJ. Mg²⁺ regulates cytotoxic functions of NK and CD8 T cells in chronic EBV infection through NKG2D. *Science*. 2013;341(6142):186-191.

2. Dibaba DT, Xun P, He K. Dietary magnesium intake is inversely associated with serum C-reactive protein levels: meta-analysis and systematic review. *Eur J Clin Nutr.* 2014;68(4):510-516.
3. Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. *Diabetes Care.* 2011;34(9):2116-2122.
4. Hartwig A. Role of magnesium in genomic stability. *Mutat Res.* 2001;475(1-2):113-121.
5. Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K. Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection. *PLoS One.* 2014;9(7):e101902.
6. Lee S, Song A, Eo W. Serum Ferritin as a Prognostic Biomarker for Survival in Relapsed or Refractory Metastatic Colorectal Cancer. *J Cancer.* 2016 May 12;7(8):957-64.
7. Lotscher J, Marti i Lindez AA, Kirchhammer N, Cribioli E, Attianese GMPG, Trefny MP, Lenz M, Rothschild SI, Strati P, Kunzli M, Lotter C, Schenk SH, Dehio P, Loliger J, Litzler L, Schreiner D, Koch V, Page N, Lee D, Grahlert J, Kuzmin D, Burgener AV, Merkle D, Pruschy M, Habicht J, Irving M, Hess C. Magnesium sensing via LFA-1 regulates CD8+ T cell effector function. *Cell.* 2022;185(4):585-602.e29.
8. Mainous AG 3rd, Gill JM, Everett CJ. Transferrin saturation, dietary iron intake, and risk of cancer. *Ann Fam Med.* 2005;3(2):131-137.
9. Pan Q, Kleer CG, van Golen KL, Irani J, Bottema KM, Bias C, De Carvalho M, Mesri EA, Robins DM, Dick RD, Brewer GJ, Merajver SD. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. *Cancer Res.* 2002;62(17):4854-4859.
10. Szymulewska-Konopko K, Reszeć-Giełazyn J, Małczek M. Ferritin as an Effective Prognostic Factor and Potential Cancer Biomarker. *Curr Issues Mol Biol.* 2025 Jan 16;47(1):60.
11. Toyokuni S. Iron and carcinogenesis: from Fenton reaction to target genes. *Redox Rep.* 2002;7(4):189-197.
12. Zhang X, Yang Q. Association between serum copper levels and lung cancer risk: a meta-analysis. *J Int Med Res.* 2018;46(12):4863-4873.

Coagulation

1. Dai H, Zhou H, Sun Y, Xu Z, Wang S, Feng T, Zhang P. D-dimer as a potential clinical marker for predicting metastasis and progression in cancer. *Biomed Rep.* 2018;9(5):453-457.
2. Li W, Tang Y, Song Y, Chen SH, Sisliyan N, Ni M, Zhang H, Zeng Q, Hou B, Xie X, Chang D. Prognostic role of pretreatment plasma D-dimer in patients with solid tumors: a systematic review and meta-analysis. *Cell Physiol Biochem.* 2018;45(4):1663-1676.
3. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirousková M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood.* 2005;105(1):178-185.
4. Perisanidis C, Psyrris A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, Stift A, Filipits M, Kornek G, Nkenke E. Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: a systematic review and meta-analysis. *Cancer Treat Rev.* 2015;41(10):960-970.

Hormones

1. Bonkhoff H. Estrogen receptor signaling in prostate cancer: implications for carcinogenesis and tumor progression. *Prostate*. 2018;78(1):2-10.
2. Barone I, Giordano C. Leptin and Beyond: Actors in Cancer. *Biomolecules*. 2021 Dec 6;11(12):1836.
3. Brinton LA, Key TJ, Kolonel LN, Michels KB, Sesso HD, Ursin G, Van Den Eeden SK, Wood SN, Falk RT, Parisi D, Guillemette C, Caron P, Turcotte V, Habel LA, Isaacs CJ, Riboli E, Weiderpass E, Cook MB. Prediagnostic sex steroid hormones in relation to male breast cancer risk. *J Clin Oncol*. 2015;33(18):2041-2050.
4. Collaborative Group on Epidemiological Studies of Ovarian Cancer; Beral V, Gaijskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet*. 2015;385(9980):1835-1842.
5. Crumbaker M, Khoja L, Joshua AM. AR signaling and the PI3K pathway in prostate cancer. *Cancers (Basel)*. 2017;9(4):34.
6. Eisermann K, Fraizer G. The androgen receptor and VEGF: mechanisms of androgen-regulated angiogenesis in prostate cancer. *Cancers (Basel)*. 2017;9(4):32.
7. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol*. 1995;85(2):304-313.
8. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. *N Engl J Med*. 1971;284(15):878-881.
9. Kanter NG, Cohen-Woods S, Balfour DA, Burt MG, Waterman AL, Koczwara B. Hypothalamic-pituitary-adrenal axis dysfunction in people with cancer: a systematic review. *Cancer Med*. 2024;13(22):e70366.
10. Key T, Appleby P, Barnes I, Reeves G; Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. *J Natl Cancer Inst*. 2002;94(8):606-616.
11. Krashin E, Piekliko-Witkowska A, Ellis M, Ashur-Fabian O. Thyroid hormones and cancer: a comprehensive review of preclinical and clinical studies. *Front Endocrinol (Lausanne)*. 2019;10:59.
12. Kwon H, Schafer JM, Song NJ, Kaneko S, Li A, Xiao T, Ma A, Allen C, Das K, Zhou L, Riesenberg B, Chang Y, Weltge P, Velegraki M, Oh DY, Fong L, Ma Q, Sundi D, Chung D, Li X, Li Z. Androgen conspires with the CD8+ T cell exhaustion program and contributes to sex bias in cancer. *Sci Immunol*. 2022;7(73):eabq2630.
13. Meng W, Liao Y, Chen J, Wang Y, Meng Y, Li K, Xiao H. Upregulation of estrogen receptor beta protein but not mRNA predicts poor prognosis and may be associated with enhanced translation in non-small cell lung cancer: a systematic review and meta-analysis. *J Thorac Dis*. 2021;13(7):4281-4300.
14. Modak S, Aktar T, Majumder D, Singha AK, Maiti D. A systematic review on leptin's role in defining cancer: special emphasis on immunomodulation, inflammation, and therapeutic interventions. *Genes Immun*. 2025 Jun;26(3):266-286.

15. Penning TM. Dehydroepiandrosterone (DHEA)-SO₄ depot and castration-resistant prostate cancer. *Vitam Horm*. 2018;108:309-331.
16. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. *J Natl Cancer Inst*. 2000;92(12):994-1000.
17. Staal J, Beyaert R. Inflammation and NF-κB signaling in prostate cancer: mechanisms and clinical implications. *Cells*. 2018;7(9):122.
18. Volden PA, Conzen SD. The influence of glucocorticoid signaling on tumor progression. *Brain Behav Immun*. 2013;30 Suppl:S26-S31.

Vitamins

1. Arendt JF, Pedersen L, Nexø E, Sørensen HT. Elevated plasma vitamin B12 levels as a marker for cancer: a population-based cohort study. *J Natl Cancer Inst*. 2013;105(23):1799-1805.
2. Han J, Guo X, Yu X, Liu S, Cui X, Zhang B, Liang H. 25-Hydroxyvitamin D and total cancer incidence and mortality: a meta-analysis of prospective cohort studies. *Nutrients*. 2019;11(10):2295.
3. Schöttker B, Jorde R, Peasey A, Thorand B, Jansen EHJM, de Groot L, et al; Consortium on Health and Ageing: Network of Cohorts in Europe and the United States. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. *BMJ*. 2014;348:g3656.

Tissue Hypoxia & Metabolic Stress

1. Ahmad F, Cherukuri MK, Choyke PL. Metabolic reprogramming in prostate cancer. *Br J Cancer*. 2021;125(9):1185-1196.
2. Bezan A, Mrcic E, Krieger D, Stojakovic T, Pummer K, Zigeuner R, Hutterer GC, Pichler M. The preoperative AST/ALT (De Ritis) ratio represents a poor prognostic factor in a cohort of patients with nonmetastatic renal cell carcinoma. *J Urol*. 2015;194(1):30-35.
3. Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. *Signal Transduct Target Ther*. 2023 Feb 17;8(1):70.
4. Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. *Cancer Biomark*. 2017;19(4):353-363.
5. Dovell F, Boffetta P. Serum uric acid and cancer mortality and incidence: a systematic review and meta-analysis. *Eur J Cancer Prev*. 2018;27(4):399-405.
6. Lazzari G, Silvano G. From Anemia to Erythropoietin Resistance in Head and Neck Squamous Cell Carcinoma Treatment: A Carousel Driven by Hypoxia. *Onco Targets Ther*. 2020 Jan 29;13:841-851.
7. Li J, Bai Z. Tumor microenvironment induces metabolic reprogramming in cancer cells. *Indian J Med Res Pharm Sci*. 2018;5(4):69-81.
8. Petrelli F, Cabiddu M, Coinu A, Borgonovo K, Ghilardi M, Lonati V, Barni S. Prognostic role of lactate dehydrogenase in solid tumors: a systematic review and meta-analysis of 76 studies. *Acta Oncol*. 2015;54(7):961-970.

9. Romero-Garcia S, Moreno-Altamirano MMB, Prado-Garcia H, Sánchez-García FJ. Lactate contribution to the tumor microenvironment: mechanisms, effects on immune cells and therapeutic relevance. *Front Immunol*. 2016;7:52.
10. Seyfried TN, Shelton LM. Cancer as a metabolic disease. *Nutr Metab (Lond)*. 2010;7:7.
11. Van Hemelrijck M, Jassem W, Walldius G, Fentiman IS, Hammar N, Lambe M, Garmo H, Jungner I, Holmberg L. Gamma-glutamyltransferase and risk of cancer in a cohort of 545,460 persons—the Swedish AMORIS study. *Eur J Cancer*. 2011;47(13):2033-2041.
12. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009;324(5930):1029-1033.
13. Yan L, Tan Y, Chen G, Fan J, Zhang J. Harnessing metabolic reprogramming to improve cancer immunotherapy. *Int J Mol Sci*. 2021;22(19):10268.
14. Zhang J, Yao YH, Li BG, Yang Q, Zhang PY, Wang HT. Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. *Sci Rep*. 2015;5:9800.

Cellular Stress

1. Chamseddine S, Yavuz BG, Mohamed YI, Lee SS, Yao JC, Hu ZI, et al. Circulating galectin-3: a prognostic biomarker in hepatocellular carcinoma. *J Immunother Precis Oncol*. 2024;7(4):255-262.
2. Nowlaczyk AU, Yu LG. Galectin-3—a jack-of-all-trades in cancer. *Cancer Lett*. 2011;313(2):123-128.
3. Scafetta G, D'Alessandria C, Bartolazzi A. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape. *J Exp Clin Cancer Res*. 2024;43(1):41.
4. Wang Y, Liu S, Tian Y, Wang Y, Zhang Q, Zhou X, et al. Prognostic role of galectin-3 expression in patients with solid tumors: a meta-analysis of 36 eligible studies. *Cancer Cell Int*. 2018;18:172.

Interstitial Acidity/Alkalinity

1. Boedtker E, Pedersen SF. The acidic tumor microenvironment as a driver of cancer. *Annu Rev Physiol*. 2020;82:103-126.
2. Suzuki K, Kachi S, Wada H. Tumor microenvironment acidosis and alkalization-oriented interventions in advanced solid tumors: a narrative review and science-based medicine perspective on long-tail survival. *Cancers (Basel)*. 2026;18(8):1193.